This compound is a pharmaceutical intermediate specifically used in the synthesis of filgotinib. It features a triazolopyridine core with a bromomethylphenyl substituent and a cyclopropanecarboxamide group, reflecting its role as a building block in pharmaceutical manufacturing.
콘텐츠 범위: 이 페이지의 정보는 화학물질 식별 및 산업 공급·연구개발·제조 맥락을 대상으로 합니다. 치료 효능 주장, 의료 조언 또는 의약품 사용 지침에 해당하지 않습니다.
이 화합물을 구매하거나 공급하시겠습니까?
재고를 등록하거나 구매 요청을 게시하세요
CAS 1206163-59-8
N-(5-(4-(hydroxymethyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide
pharmaceutical intermediate
(5-Bromo-3-(trifluoromethyl)pyridin-2-yl)methanol
pharmaceutical intermediate
5-Deamino-5-oxo Amiloride Hydrochloride
pharmaceutical impurity reference standard
(2S,3S)-2-Amino-3-methyl-3-sulfino-4-(1H-1,2,3-triazol-1-yl)butyric acid
Tazobactam metabolite M1 reference standard
(5R,6S)-Allyl 6-((R)-1-((tert-butyldimethylsilyl)oxy)ethyl)-7-oxo-3-((R)-tetrahydrofuran-2-yl)-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate
synthetic beta-lactam intermediate
N-(5-(4-formylphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide
Pharmaceutical intermediate for Filgotinib synthesis
N-[5-[4-(bromomethyl)phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide
NEOZIFRQXFFBFZ-UHFFFAOYSA-N
C1CC1C(=O)NC2=NN3C(=N2)C=CC=C3C4=CC=C(C=C4)CBr
—